NANOTECHNOLOGY: EMERGING ERA FOR AUTOIMMUNE DISEASES

Shrikant Dod*, Nitin Padole, Nilakshi Dhoble, Pankaj Dhapke and Jagdish Baheti

ABSTRACT

The therapy options for autoimmune illnesses, in which the body's immune system attacks its own tissues, are being completely transformed by nanotechnology. Conventional treatments for these conditions depend on widespread immunosuppression, which frequently has unfavourable side effects. The development of nanotechnology presents a fresh and exciting substitute. With sizes ranging from one to 100 nanometres, nanoparticles provide a novel approach to immunological regulation, targeted medication delivery, and the development of antigen-specific tolerance. Their tiny size enables accurate interactions at the cellular level, which makes it possible to diagnose diseases early and develop customized medicines. The continuous medication release provided by these particles—which are usually biodegradable—is especially helpful in the treatment of long-term autoimmune diseases. Nanoparticles can transport therapeutic compounds directly to the region of action, limiting off-target effects and optimizing therapy efficacy, by accurately targeting afflicted tissues or cells. Additionally, they may be able to control immunological responses and the hyperactive immune system that characterizes autoimmune disorders. Despite these encouraging prospects, more investigation via thorough study, clinical trials, and regulatory clearances is necessary to fully realize the promise of nanotechnology in treating autoimmune illnesses. For those suffering from autoimmune diseases, this new age of nanotechnology-driven medicines has the potential to greatly improve treatment results and quality of life. The search for these breakthroughs might result in safer, more focused, and more potent therapies, bringing in a revolutionary period in the treatment of autoimmune diseases.

Keywords: Nanotechnology, Autoimmune Diseases, Targeted Drug Delivery, improving patient Therapies, Immunomodulation.